Who
Camille L. Bedrosian
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Amylyx Pharmaceuticals; Director, Crinetics Pharmaceuticals; Director, Rhythm Pharmaceuticals; EVP and Chief Medical Officer, Ultragenyx Pharmaceutical; VP, Chief Medical Officer, Ariad Pharmaceuticals.
In numbers
- Trades disclosed
- 107
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $7.3M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 16 Apr 2007
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $256K7,947 at $32.21 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $69K2,081 at $33.09 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $256K7,947 at $32.21 | filing |
| 10 Sep 2026filed 14 Sep 2026 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $69K2,081 at $33.09 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $1.4M16,300 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $504K5,925 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.7M25,000 at $68.92 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.7M25,000 at $68.92 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.77 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.2M17,500 at $66.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.77 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.2M17,500 at $66.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $39.00AMLX · dailypolitical.com · 18 Oct 2026Insider Selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Sells 30,000 Shares of StockAMLX · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Camille L. Bedrosian; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.